ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) today reported a positive outcome of its large, formal pharmacokinetic (PK) study of its investigational drug Zenvia™ (dextromethorphan/quinidine [DM/Q]). The objective of the formal PK study was to support identification of an alternative dosing formulation of Zenvia designed to deliver similar efficacy as observed in the first Phase III clinical study in diabetic peripheral neuropathic (DPN) pain but with an improved safety and tolerability profile. The study achieved its goal of identifying a new Zenvia dosing regimen that provides a similar pharmacokinetic profile of the dextromethorphan component, an improved adverse event profile and a lower overall exposure to quinidine compared to the previously studied doses. AVANIR believes that these study results can be used to enhance its worldwide intellectual property protection and intends to release detailed data, including PK parameters, after they are incorporated into the Zenvia patent portfolio.
